Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

By G. Juliusson, P. Antunović, A. Derolf, S. Lehmann, L. Möllgård, D. Stockelberg, U. Tidefelt, A. Wåhlin, M. Höglund. Blood, 2009

999 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/accc48680f34e9486af7718d361e09c8adf370f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. J. Cortes

In Molecular Biology

1. M. Wieduwilt

Citations in the corpus

• Therapeutic advances in acute myeloid leukemia. (2011, neutral): “Median age is around 70 years, and physicians or patients are reluctant to undertake intensive chemotherapy.(59,60) High age independently defines unfavorable disease outcome.”
• CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia (2018, background): “Multiple studies have demonstrated low remission rates and reduced survival in patients with high-risk AML, including sAML and AML with adverse-risk karyotypes.(2,4,13,27,28) However, few randomized studies have independently reported the effect of novel therapies in these patients.”